NASDAQ:IKNA Ikena Oncology Q1 2025 Earnings Report $1.38 -0.01 (-0.72%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 07/11/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Ikena Oncology EPS ResultsActual EPS-$0.18Consensus EPS -$0.21Beat/MissBeat by +$0.03One Year Ago EPSN/AIkena Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIkena Oncology Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time9:30AM ETUpcoming EarningsIkena Oncology's Q2 2025 earnings is scheduled for Thursday, August 14, 2025Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Ikena Oncology Earnings HeadlinesIkena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene BiopharmaceuticalsJuly 11 at 8:00 AM | globenewswire.comIkena Oncology (NASDAQ:IKNA) Shares Up 1.5% - Here's What HappenedJuly 9, 2025 | americanbankingnews.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 13 at 2:00 AM | Timothy Sykes (Ad)Ikena Oncology Reports Q1 Loss Amid Merger PlansMay 27, 2025 | tipranks.comIkena Oncology: Investor Caution as Dividend Payments Remain UnlikelyMarch 7, 2025 | tipranks.comDiscovering February 2025's Promising Penny Stocks On US ExchangesFebruary 14, 2025 | finance.yahoo.comSee More Ikena Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email. Email Address About Ikena OncologyIkena Oncology (NASDAQ:IKNA), headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small-molecule therapies for cancer. Since its founding in 2016, the company has built a pipeline targeting key processes in tumor cell division and chromatin regulation, aiming to address unmet needs in solid tumors and hematologic malignancies. The company’s lead clinical candidates include a selective polo-like kinase 1 (PLK1) inhibitor designed to disrupt mitotic progression in advanced solid tumors and an inhibitor of the KDM5 family of histone demethylases that modulates epigenetic drivers of cancer cell survival. Additional preclinical programs are exploring novel targets implicated in oncogenic signaling and tumor resistance mechanisms. Ikena retains global development and commercialization rights for its internal portfolio and leverages collaborations with leading academic research centers to advance its pipeline. Ikena operates research and development facilities in Cambridge and conducts multi-site clinical studies across North America and Europe. The company’s projects are supported by strategic partnerships and investigator-initiated trials aimed at optimizing patient selection and combination strategies. Manufacturing and scale-up activities are managed through experienced contract development and manufacturing organizations (CDMOs) in accordance with regulatory standards. The leadership team at Ikena Oncology brings decades of combined experience in oncology drug development, regulatory affairs, and commercialization, with former executives and scientific leaders from industry-leading organizations. This management group guides the company’s clinical advancement and strategic planning as Ikena progresses toward regulatory filings and potential first‐in‐class approvals.Written by Jeffrey Neal JohnsonView Ikena Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
